Explore › Condition › Education about postpartum depression
Condition

Education about postpartum depression

Also known as: Education about postpartum depression Education about postpartum depression (procedure) postpartum depression; anxiety PPD
3 findings 1 paper 4 related entities View in graph →

Related entities

interventions
PREPP (Practical Resources for Effective Postpartum Parenting)1
outcomes
anxiety symptoms1
populations
Postmenopausal Women1
studys
PMC47381661

Findings (27)

None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →
None
improvement

Women who received PREPP decreased significantly in clinician-rated anxiety symptoms (HAM-A) between pre-randomization and 6 weeks postpartum, with effects persisting to 16 weeks, while ETAU women sho

Effect: improvement; B = −7.84

Size: B = −7.84
PMC4738166
Finding details → · Paper → · Graph →

Papers (1)